STAT3 and ovarian carcinoma: In the case of recurrent ovarian carcinoma, tocilizumab decreased STAT3 activation/phosphorylation in patient immune cells (e.g., myeloid cells, CD4+ T and CD8+ T only at a high dose), most probably due to the suppression of IL-6R signalling [88].